Figure 1 (Dapagliflozin 1 Figure)
Dapagliflozin Tablet, Film Coated
Product Images NDC 46708-393
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 46708-393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
30 Tablets (Dapagliflozin 10)
Figure 4 (Dapagliflozin 4 Figure)
This data seems to be related to a clinical trial comparing Dapagifiazin tablets with a placebo in patients over a period of months from randomization. The table shows the percentage of events in patients at different time points. The number of patients at risk in each group is also provided.*
Figure 5 (Dapagliflozin 5 Figure)
30 Tablets (Dapagliflozin 5)
Figure 2 (Dapagliflozin Figure2)
This is a comparison of the adjusted mean change from baseline HbA1c (%) over time for individuals treated with Dapagliflozin tablets 10 mg + Metformin. The graph shows results for subjects who completed the study at Week 24 without rescue. The study includes randomized subjects with baseline and at least one post-baseline HbA1c measurement before rescue.*
Figure 3 (Dapagliflozin Figure3)
Structure (Dapagliflozin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
